UY27533A1 - Composiciones farmacéuticas que contienen oxibutinina - Google Patents
Composiciones farmacéuticas que contienen oxibutininaInfo
- Publication number
- UY27533A1 UY27533A1 UY27533A UY27533A UY27533A1 UY 27533 A1 UY27533 A1 UY 27533A1 UY 27533 A UY27533 A UY 27533A UY 27533 A UY27533 A UY 27533A UY 27533 A1 UY27533 A1 UY 27533A1
- Authority
- UY
- Uruguay
- Prior art keywords
- oxibutinine
- pharmaceutical compositions
- compositions containing
- drugs
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
Abstract
Se provee una composición farmacéutica y una forma de dosificación para el tratamiento de la incontinencia. La forma de dosificación puede incluir cantidades terapéuticas o subterapéuticas de una o ambas drogas. El dispositivo osmótico provee una liberación controlada de ambas drogas desde el núcleo. Se provee un método para el tratamiento de la incontinencia urinaria (por estrés o urgencia). Juntas, la oxibutinina y la segunda droga proveen un beneficio clínico general mejorado con relación a los agentes administrados solos y aproximadamente en la misma dosis.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/992,488 US20030185882A1 (en) | 2001-11-06 | 2001-11-06 | Pharmaceutical compositions containing oxybutynin |
Publications (1)
Publication Number | Publication Date |
---|---|
UY27533A1 true UY27533A1 (es) | 2003-05-30 |
Family
ID=25538393
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY27532A UY27532A1 (es) | 2001-11-06 | 2002-11-06 | Forma de dosificación de liberación controlada dual. |
UY27533A UY27533A1 (es) | 2001-11-06 | 2002-11-06 | Composiciones farmacéuticas que contienen oxibutinina |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY27532A UY27532A1 (es) | 2001-11-06 | 2002-11-06 | Forma de dosificación de liberación controlada dual. |
Country Status (7)
Country | Link |
---|---|
US (2) | US20030185882A1 (es) |
EP (1) | EP1461018A2 (es) |
AR (2) | AR037256A1 (es) |
AU (2) | AU2002363360A1 (es) |
BR (1) | BR0213948A (es) |
UY (2) | UY27532A1 (es) |
WO (2) | WO2003039519A2 (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR018321A1 (es) * | 1998-03-26 | 2001-11-14 | Alza Corp | Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada. |
US8329217B2 (en) | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
TW200302748A (en) * | 2002-02-01 | 2003-08-16 | Pfizer Prod Inc | Osmotic delivery system |
EP2085072A1 (en) * | 2002-03-26 | 2009-08-05 | Teva Pharmaceutical Industries Ltd. | Drug microparticles |
AR039744A1 (es) * | 2002-06-26 | 2005-03-09 | Alza Corp | Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada |
AU2003256848A1 (en) * | 2002-07-29 | 2004-02-16 | Alza Corporation | Formulations and dosage forms for controlled delivery of topiramate |
US20050232995A1 (en) | 2002-07-29 | 2005-10-20 | Yam Nyomi V | Methods and dosage forms for controlled delivery of paliperidone and risperidone |
US7785627B2 (en) * | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US20050271691A1 (en) * | 2003-02-21 | 2005-12-08 | Cardio Combos Llc | Prepackaged aqueous pharmaceutical formulations |
US20050058707A1 (en) * | 2003-08-06 | 2005-03-17 | Iran Reyes | Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation |
EP2210605B1 (en) * | 2003-11-04 | 2017-03-01 | TCD Royalty Sub, LLC | Once daily dosage forms of trospium |
EP1680100A4 (en) | 2003-11-04 | 2012-08-08 | Supernus Pharmaceuticals Inc | QUATERNARY AMMONIUM COMPOUNDS CONTAINING BIOAVAILABILITY ACTIVATORS |
JP2007517063A (ja) * | 2003-12-29 | 2007-06-28 | アルザ・コーポレーシヨン | トピラメートの新規な薬剤組成物および剤形 |
EP1701706A2 (en) * | 2003-12-29 | 2006-09-20 | Alza Corporation | Novel drug compositions and dosage forms |
US20050175696A1 (en) * | 2003-12-29 | 2005-08-11 | David Edgren | Drug granule coatings that impart smear resistance during mechanical compression |
JP2007522249A (ja) * | 2004-02-13 | 2007-08-09 | ニューロモレキュラー・インコーポレイテッド | 精神医学的状態の処置のための、nmdaレセプターアンタゴニストと、抗うつ薬であるmaoインヒビターまたはgadphインヒビターとの併用 |
WO2005105036A1 (en) * | 2004-04-28 | 2005-11-10 | Natco Pharma Limited | Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation |
EP1629834A1 (en) * | 2004-08-27 | 2006-03-01 | KRKA, D.D., Novo Mesto | Sustained release pharmaceutical composition of tolterodine |
AR053986A1 (es) | 2004-12-03 | 2007-05-30 | Osmotica Pharmaceutical Argent | Dispositivo osmotico que contiene amantadina y una sal osmotica |
DE05815688T1 (de) | 2005-01-27 | 2008-06-26 | Alembic Ltd. | Levetiracetam-formulierung mit verlängerter freisetzung |
JP5095615B2 (ja) | 2005-06-27 | 2012-12-12 | バリアント・インターナショナル・(バルバドス)・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ | ブプロピオン塩の放出調整製剤 |
EP2032124A1 (en) * | 2006-06-27 | 2009-03-11 | Biovail Laboratories International Srl | Multiparticulate osmotic delivery system |
US20080014264A1 (en) * | 2006-07-13 | 2008-01-17 | Ucb, S.A. | Novel pharmaceutical compositions comprising levetiracetam |
US8486452B2 (en) * | 2007-07-20 | 2013-07-16 | Mylan Pharmaceuticals Inc. | Stabilized tolterodine tartrate formulations |
US8110226B2 (en) * | 2007-07-20 | 2012-02-07 | Mylan Pharmaceuticals Inc. | Drug formulations having inert sealed cores |
US8871275B2 (en) | 2007-08-08 | 2014-10-28 | Inventia Healthcare Private Limited | Extended release compositions comprising tolterodine |
WO2009052353A2 (en) * | 2007-10-17 | 2009-04-23 | Dr. Reddy's Laboratories Ltd. | Trospium pharmaceutical formulations |
WO2010089259A2 (en) | 2009-02-04 | 2010-08-12 | Woerwag R&D Gmbh | Sustained release composition containing quetiapine |
WO2011161504A1 (en) * | 2010-06-23 | 2011-12-29 | Micro Labs Limited | Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof |
CN102048706B (zh) * | 2011-01-12 | 2012-02-22 | 山东创新药物研发有限公司 | 一种氢溴酸达非那新缓释片及制备方法 |
CN103156804A (zh) * | 2011-12-13 | 2013-06-19 | 重庆医药工业研究院有限责任公司 | 一种奥昔布宁透皮凝胶及其制备方法 |
CA2873961C (en) * | 2012-05-14 | 2017-09-26 | Shionogi & Co., Ltd. | Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives |
CN103127023B (zh) * | 2013-03-01 | 2014-08-27 | 河北天成药业股份有限公司 | 一种盐酸度洛西汀肠溶片及其制备方法 |
GB201708224D0 (en) * | 2017-05-23 | 2017-07-05 | Juniper Pharmaceuticals Uk Ltd | Device |
JP7422666B2 (ja) * | 2018-01-30 | 2024-01-26 | アプニメッド,インコーポレイテッド(デラウェア) | 睡眠時無呼吸を治療するための方法および組成物 |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4111202A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
US4309996A (en) * | 1980-04-28 | 1982-01-12 | Alza Corporation | System with microporous releasing diffusor |
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4455143A (en) * | 1982-03-22 | 1984-06-19 | Alza Corporation | Osmotic device for dispensing two different medications |
US4449983A (en) * | 1982-03-22 | 1984-05-22 | Alza Corporation | Simultaneous delivery of two drugs from unit delivery device |
US4681583A (en) * | 1982-12-20 | 1987-07-21 | Alza Corporation | System for dispersing drug in biological environment |
US4552880A (en) * | 1983-02-15 | 1985-11-12 | Merrell Dow Pharmaceuticals Inc. | Aroylimidazolones |
US4612008A (en) * | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US4765989A (en) * | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
US5082668A (en) * | 1983-05-11 | 1992-01-21 | Alza Corporation | Controlled-release system with constant pushing source |
US4627971A (en) * | 1985-04-22 | 1986-12-09 | Alza Corporation | Osmotic device with self-sealing passageway |
US4624847A (en) * | 1985-04-22 | 1986-11-25 | Alza Corporation | Drug delivery device for programmed delivery of beneficial drug |
US4661583A (en) * | 1985-06-24 | 1987-04-28 | Ashland Oil, Inc. | Reaction of bicyclic amide acetal with imide |
US4971790A (en) * | 1986-02-07 | 1990-11-20 | Alza Corporation | Dosage form for lessening irritation of mocusa |
US4723957A (en) * | 1986-02-07 | 1988-02-09 | Alza Corp. | System for delivering drug with enhanced bioacceptability |
US4867969A (en) * | 1986-02-07 | 1989-09-19 | Alza Corporation | Hydrogel formulation for administering non-steroidal drugs |
US4662880A (en) * | 1986-03-14 | 1987-05-05 | Alza Corporation | Pseudoephedrine, brompheniramine therapy |
US4863456A (en) * | 1986-04-30 | 1989-09-05 | Alza Corporation | Dosage form with improved delivery capability |
US4960416A (en) * | 1986-04-30 | 1990-10-02 | Alza Corporation | Dosage form with improved delivery capability |
US5082663A (en) * | 1986-08-20 | 1992-01-21 | Teikoku Seiyaky Co., Ltd. | External adhesive preparation containing steroids |
US4765957A (en) * | 1986-12-29 | 1988-08-23 | Carondelet Foundry Company | Alloy resistant to seawater and other corrosive fluids |
DE3716260C1 (de) * | 1987-05-15 | 1988-07-28 | Dyckerhoff & Widmann Ag | Verfahren zur Justierung und Befestigung von Funktionsflaechen eines Fahrwegs einer elektromagnetischen Schnellbahn und Vorrichtung zur Durchfuehrung des Verfahrens |
US5236689A (en) * | 1987-06-25 | 1993-08-17 | Alza Corporation | Multi-unit delivery system |
US4814181A (en) * | 1987-09-03 | 1989-03-21 | Alza Corporation | Dosage form comprising fast agent delivery followed by slow agent delivery |
US4915954A (en) * | 1987-09-03 | 1990-04-10 | Alza Corporation | Dosage form for delivering a drug at two different rates |
US4996061A (en) * | 1987-10-07 | 1991-02-26 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutical composition for piperidinoalkanol-decongestant combination |
US4904474A (en) | 1988-01-25 | 1990-02-27 | Alza Corporation | Delivery of drug to colon by oral disage form |
US5160743A (en) * | 1988-04-28 | 1992-11-03 | Alza Corporation | Annealed composition for pharmaceutically acceptable drug |
US5006346A (en) | 1988-04-28 | 1991-04-09 | Alza Corporation | Delivery system |
US4931285A (en) * | 1988-04-28 | 1990-06-05 | Alza Corporation | Aqueous based pharmaceutical coating composition for dosage forms |
US5006348A (en) * | 1990-05-04 | 1991-04-09 | Kraft General Foods, Inc. | Method for manufacture of swiss cheese |
ATE86440T1 (de) * | 1990-06-13 | 1993-03-15 | Manfred Oelsner | Verfahren zur herstellung von pektin- und zuckerhaltigen zubereitungen, wie konfituere, marmelade od.gdl. |
US5976571A (en) * | 1991-01-31 | 1999-11-02 | Port Systems, L.L.C. | Method for making a multi-stage drug delivery system |
US5208037A (en) * | 1991-04-22 | 1993-05-04 | Alza Corporation | Dosage forms comprising polymers comprising different molecular weights |
US5160744A (en) * | 1991-06-27 | 1992-11-03 | Alza Corporation | Verapmil therapy |
US5190765A (en) | 1991-06-27 | 1993-03-02 | Alza Corporation | Therapy delayed |
US5252338A (en) * | 1991-06-27 | 1993-10-12 | Alza Corporation | Therapy delayed |
JP2646170B2 (ja) | 1992-06-24 | 1997-08-25 | 日本ヘキスト・マリオン・ルセル株式会社 | 徐放性塩酸オキシブチニン製剤 |
US5643155A (en) * | 1993-11-02 | 1997-07-01 | Kallassy; Charles | Aquatic exercise device |
HU213407B (en) * | 1993-12-09 | 1997-06-30 | Egyt Gyogyszervegyeszeti Gyar | Process for producing tablet with diffusive-osmotic release |
US5399359A (en) * | 1994-03-04 | 1995-03-21 | Edward Mendell Co., Inc. | Controlled release oxybutynin formulations |
AU7994694A (en) | 1994-10-21 | 1996-05-15 | Leiras Oy | Controlled release oral delivery system containing oxybutynin |
US5677346A (en) * | 1995-01-31 | 1997-10-14 | Sepracor, Inc. | Treating urinary incontinence using (S)-desethyloxybutynin |
US5674895A (en) * | 1995-05-22 | 1997-10-07 | Alza Corporation | Dosage form comprising oxybutynin |
US5912268A (en) * | 1995-05-22 | 1999-06-15 | Alza Corporation | Dosage form and method for treating incontinence |
GB9518953D0 (en) * | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO1997016814A1 (en) | 1995-11-03 | 1997-05-09 | Sierra Semiconductor Corporation | Yuv video backend filter |
JP2665658B2 (ja) | 1995-12-18 | 1997-10-22 | 住友特殊金属株式会社 | 希土類・鉄・コバルト・ボロン系正方晶化合物 |
DK0914097T3 (da) * | 1996-03-12 | 2002-04-29 | Alza Corp | Sammensætning og doseringsform omfattende opioid antagonist |
US5788987A (en) * | 1997-01-29 | 1998-08-04 | Poli Industria Chimica Spa | Methods for treating early morning pathologies |
ES2141044B1 (es) * | 1997-02-26 | 2001-02-01 | Alza Corp | Terapia con oxibutinina. |
US5866184A (en) * | 1997-03-12 | 1999-02-02 | World Class Packaging Systems, Inc. | Method of packaging a food product in a ventable package |
IL128043A (en) * | 1997-05-30 | 2004-08-31 | Osmotica Corp | Multi-layered osmotic device for controlled delivery of active agents |
ME00850B (me) | 1998-08-27 | 2008-08-07 | Pfizer Health Ab | Nove perle sa kontrolisanim oslobađanjem, postupak za njihovu proizvodnju i višestruka jedinična formulacija koja ih sadrži |
WO2000019997A1 (en) | 1998-10-07 | 2000-04-13 | Alza Corporation | Controlled release dosage from comprising oxybutynin |
US6562368B2 (en) * | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers |
IL141235A (en) * | 2000-02-09 | 2012-04-30 | Novartis Int Pharm Ltd | Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia |
CN1396829A (zh) * | 2000-02-24 | 2003-02-12 | 法玛西雅厄普约翰美国公司 | 新的药物联合形式 |
US8329217B2 (en) | 2001-11-06 | 2012-12-11 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dual controlled release dosage form |
-
2001
- 2001-11-06 US US09/992,488 patent/US20030185882A1/en not_active Abandoned
-
2002
- 2002-11-06 AR ARP020104231A patent/AR037256A1/es not_active Application Discontinuation
- 2002-11-06 BR BR0213948-0A patent/BR0213948A/pt not_active Application Discontinuation
- 2002-11-06 WO PCT/CR2002/000006 patent/WO2003039519A2/es not_active Application Discontinuation
- 2002-11-06 AR ARP020104230A patent/AR037255A1/es not_active Application Discontinuation
- 2002-11-06 UY UY27532A patent/UY27532A1/es not_active Application Discontinuation
- 2002-11-06 UY UY27533A patent/UY27533A1/es not_active Application Discontinuation
- 2002-11-06 EP EP02798241A patent/EP1461018A2/en not_active Withdrawn
- 2002-11-06 AU AU2002363360A patent/AU2002363360A1/en not_active Abandoned
- 2002-11-06 WO PCT/CR2002/000007 patent/WO2003039436A2/es not_active Application Discontinuation
- 2002-11-06 AU AU2002363361A patent/AU2002363361A1/en not_active Abandoned
-
2005
- 2005-12-29 US US11/321,736 patent/US8241667B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
UY27532A1 (es) | 2003-05-30 |
BR0213948A (pt) | 2004-08-31 |
US20030185882A1 (en) | 2003-10-02 |
AR037255A1 (es) | 2004-11-03 |
WO2003039519A3 (es) | 2004-03-25 |
AU2002363360A1 (en) | 2003-05-19 |
US20060177510A1 (en) | 2006-08-10 |
WO2003039436A3 (es) | 2004-02-26 |
WO2003039519A2 (es) | 2003-05-15 |
WO2003039436A2 (es) | 2003-05-15 |
AU2002363361A1 (en) | 2003-05-19 |
US8241667B2 (en) | 2012-08-14 |
EP1461018A2 (en) | 2004-09-29 |
AR037256A1 (es) | 2004-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY27533A1 (es) | Composiciones farmacéuticas que contienen oxibutinina | |
US20190216779A1 (en) | Use of neurokinin-1 antagonists to treat a variety of pruritic conditions | |
ES2178430T3 (es) | Utilizacion de composiciones farmaceuticas gelificables en parodontologia. | |
BRPI0015567B8 (pt) | composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica | |
UY29182A1 (es) | "derivados de bencenosulfonamidas sustituídas, composiciones que las contienen, procedimientos de preparación y aplicaciones" | |
SG157406A1 (en) | Oral medicament for the modified release of at least one active principle, in multi-microcapsule form | |
NO20043871L (no) | Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid | |
ATE235895T1 (de) | Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis | |
ATE306266T1 (de) | Verbesserte verabreichungstechnik für multiple medikamentengaben | |
ES2109899T1 (es) | Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos. | |
AR045972A1 (es) | Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas | |
AR049985A1 (es) | Tratamiento de combinacion para enfermedades malignas no hematologicas | |
PE20040134A1 (es) | Forma de dosificacion de una vez al dia de pramipexol | |
AR051099A1 (es) | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas | |
UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
AR033688A1 (es) | Composicion parenteral reconstituible | |
UY29905A1 (es) | Formulación farmacéutica de absorción oral y su método de administración | |
AR018862A1 (es) | Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion | |
ECSP066318A (es) | Composición para la liberación de una base debil por un periodo extendido de tiempo | |
BR0311414A (pt) | Agente terapêutico para uma bexiga hiperativa | |
AR030039A1 (es) | Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento | |
CO5190664A1 (es) | Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2 | |
CO5580741A2 (es) | Composicion farmaceutica que comprende un agonista de receptor de 5ht1 | |
AR046951A1 (es) | Moduladores de los receptores nucleares de hormonas esteroides triciclicos | |
AR046410A1 (es) | Composiciones farmaceuticas para la liberacion modificada de modafinilo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20150126 |